Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
Status: Recruiting
Location: See all (51) locations...
Study Type: Observational
SUMMARY
The main aim of this study is to assess real-world effectiveness of nemolizumab in Prurigo nodularis (PN) as measured by investigator and patient reported outcome (PRO) in clinical practice at Month 6.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Participants who, according to the treating physician's decision and in line with the local package label, are newly initiated on nemolizumab (Nemluvio®) for the treatment of PN.
• Participants greater than or equal to (\>=) 18 years of age.
• Participants who signed the written informed consent form (ICF).
Locations
United States
Alabama
Galderma Investigational Site # 8893
NOT_YET_RECRUITING
Birmingham
Arizona
Galderma Investigational Site # 7060
NOT_YET_RECRUITING
Phoenix
Galderma Investigational Site # 7077
NOT_YET_RECRUITING
Phoenix
Galderma Investigational Site # 7067
NOT_YET_RECRUITING
Tucson
California
Galderma Investigational Site # 7074
NOT_YET_RECRUITING
Corona
Galderma Investigational Site # 6836
NOT_YET_RECRUITING
Fountain Valley
Galderma Investigational Site # 8224
NOT_YET_RECRUITING
Fremont
Galderma Investigational Site # 7064
NOT_YET_RECRUITING
Santa Monica
Colorado
Galderma Investigational Site # 7061
NOT_YET_RECRUITING
Castle Rock
Connecticut
Galderma Investigational Site # 7059
NOT_YET_RECRUITING
Fairfield
Florida
Galderma Investigational Site # 7087
NOT_YET_RECRUITING
Coral Gables
Galderma Investigational Site # 7063
NOT_YET_RECRUITING
Cutler Bay
Galderma Investigational Site # 7078
NOT_YET_RECRUITING
Miami
Galderma Investigational Site # 7070
NOT_YET_RECRUITING
North Miami Beach
Galderma Investigational Site # 7091
NOT_YET_RECRUITING
Tampa
Illinois
Galderma Investigational Site # 7058
NOT_YET_RECRUITING
Chicago
Indiana
Galderma Investigational Site # 8142
NOT_YET_RECRUITING
Indianapolis
Massachusetts
Galderma Investigational Site # 7065
NOT_YET_RECRUITING
Brighton
Maryland
Galderma Investigational Site # 8012
NOT_YET_RECRUITING
Glendale
Galderma Investigational Site # 7068
NOT_YET_RECRUITING
Rockville
Michigan
Galderma Investigational Site # 7066
NOT_YET_RECRUITING
Auburn Hills
Galderma Investigational Site # 7071
NOT_YET_RECRUITING
Caledonia
Galderma Investigational Site # 7072
NOT_YET_RECRUITING
Troy
Galderma Investigational Site # 7053
NOT_YET_RECRUITING
Waterford
Missouri
Galderma Investigational Site # 7057
NOT_YET_RECRUITING
Lee's Summit
Galderma Investigational Site # 7076
NOT_YET_RECRUITING
St Louis
New Hampshire
Galderma Investigational Site # 7055
RECRUITING
Portsmouth
New York
Galderma Investigational Site # 7080
NOT_YET_RECRUITING
Auburn
Galderma Investigational Site # 7052
NOT_YET_RECRUITING
East Syracuse
Galderma Investigational Site # 8282
NOT_YET_RECRUITING
Mount Kisco
Galderma Investigational Site # 7051
NOT_YET_RECRUITING
New York
Galderma Investigational Site # 7056
NOT_YET_RECRUITING
New York
Ohio
Galderma Investigational Site # 7081
NOT_YET_RECRUITING
Dayton
Pennsylvania
Galderma Investigational Site # 8559
NOT_YET_RECRUITING
Philadelphia
Texas
Galderma Investigational Site # 8238
NOT_YET_RECRUITING
Dallas
Galderma Investigational Site # 7062
NOT_YET_RECRUITING
Edinburg
Galderma Investigational Site # 7088
NOT_YET_RECRUITING
Grapevine
Galderma Investigational Site # 7069
NOT_YET_RECRUITING
Sugar Land
Virginia
Galderma Investigational Site # 7079
NOT_YET_RECRUITING
Vienna
Other Locations
Germany
Galderma Investigational Site # 6387
NOT_YET_RECRUITING
Ahaus
Galderma Investigational Site # 6385
NOT_YET_RECRUITING
Berlin
Galderma Investigational Tracker Site # 6172
NOT_YET_RECRUITING
Berlin
Galderma Investigational Site # 6386
NOT_YET_RECRUITING
Bielefeld
Galderma Investigational Site # 6369
NOT_YET_RECRUITING
Erlangen
Galderma Investigational Site # 6370
NOT_YET_RECRUITING
Haslach
Galderma Investigational Site # 6374
NOT_YET_RECRUITING
Karlsruhe
Galderma Investigational Site # 5437
NOT_YET_RECRUITING
Kiel
Galderma Investigational Site # 6384
NOT_YET_RECRUITING
Koblenz
Galderma Investigational Site # 6373
NOT_YET_RECRUITING
Mainz
Galderma Investigational Site # 6371
NOT_YET_RECRUITING
Oberursel
Galderma Investigation Site # 6367
NOT_YET_RECRUITING
Rostock
Contact Information
Primary
Galderma Research and Development
clinical.studies@galderma.com
817-961-5000
Time Frame
Start Date: 2025-08-11
Estimated Completion Date: 2027-11-30
Participants
Target number of participants: 600
Treatments
Nemolizumab
Participants with moderate-to-severe PN who are receiving nemolizumab (Nemluvio®) in routine clinical practice will be observed for approximately 12 months.
Related Therapeutic Areas
Sponsors
Leads: Galderma R&D